Association of Pharmaceutical Industry Marketing of Opioid Products to Physicians With Subsequent Opioid Prescribing
Despite the increasing contribution of heroin and illicitly manufactured fentanyl to opioid-related overdose deaths in the United States, 40% of deaths involve prescription opioids. 1 Presc ription opioids are commonly the first opioid encountered in a trajectory toward illicit consumption. 2 Although opioid prescribing has declined nationally, rates in 2015 were triple those in 1999 and remain elevated in regions of the country with higher numbers of overdoses. 3 Pharmaceutical industry marketing to physicians is widespread, but it is unclear whether marketing of opioids influences prescribing. 4 We studied the extent to which pharmaceutical industry marketing of opioid products to physicians during 2014 was associated with opioid prescribing during 2015. Methods | We linked 2 US databases. From the Open Payments database, we obtained information on all transfers of value from pharmaceutical companies to physicians ("payments") during 2014. 5 We identified all nonresearch payments involving opioid products, excluding buprenorphine hydrochloride marketed for addiction treatment. From the Medicare Part D Opioid Prescriber Summary File, we obtained information on all claims from physicians who wrote opioid prescriptions (initial or refill) filled for Medicare beneficiaries during 2015. 6 We included all physicians with complete, nonduplicate information who had at least 10 opioid claims during 2015, and matched physicians across databases using name and location. 7 We analyzed 2015 opioid claims in relation to marketing using multiple linear regression. Covariates included 2014 opioid claims and the change in total drug claims from 2014 to 2015. We also analyzed 2015 opioid claims in relation to opioid-related marketing meals in 2014, adjusting for these covariates and receipt of industry payments other than meals. Claims were log 10 -transformed to address skewed data. The study was considered exempt by the Brown University Institutional Review Board. (Table) .
Each meal received in 2014 was associated with an increasing number of opioid claims in 2015 (Figure) . In multivariable modeling, each additional meal was associated with an increase of 0.7% (95% CI, 0.6%-0.8%) in opioid claims. b Includes (in descending order of total dollars of payments received) psychiatry, emergency medicine, obstetrics/gynecology, otolaryngology, pediatrics, ophthalmology, and dermatology (all with <$100 000 in total payments).
Discussion | Of physicians who prescribed opioids under Medicare Part D, 7.0% received nonresearch payments related to opioid products in 2014. These payments were associated with greater opioid prescribing in 2015. One company, INSYS Therapeutics, accounted for 50% of the nonresearch payments. Our findings add to prior studies of industry marketing to physicians by examining receipt of payments in 1 year and prescribing in the subsequent year, and adjusting for overall prescribing trends.
Limitations include the possibility of reverse causality because physicians who receive industry payments may be predisposed to prescribe opioids. Our findings establish an association, not cause and effect.
Amidst national efforts to curb the overprescribing of opioids, our findings suggest that manufacturers should consider a voluntary decrease or complete cessation of marketing to physicians. Federal and state governments should also consider legal limits on the number and amount of payments. In this systematic review and meta-analysis, 1 we assessed whether oral vitamin K (phytonadione and menaquinone-4) supplementation was associated with a reduction in bone loss and prevention of fractures. We included 13 trials with data on bone loss, and 7 of these trials reported fracture data. We reported that all studies but 1 showed an association of phytonadione and menaquinone-4 with reduction of bone loss. All 7 trials that had reported data on fractures were Japanese and used menaquinone-4. We reported: "Pooling the 7 trials with fracture data in a meta-analysis, we found an odds ratio (OR) favoring menaquinone-4 of 0. undertook a sensitivity analysis excluding those 3 trials (Figure 4 in our article), which resulted in the differences in hip fracture effectiveness being no longer statistically significant. 1 As we reported in the Results section of our original article, "Because 1 of the centers provided most of the data for hip fractures and this center had included populations with a very high fracture risk, [33] [34] [35] we undertook a sensitivity analysis excluding data from this center. The OR for hip fractures for the remaining 2 studies when combined was 0.30 (still a large effect); however, this finding was no longer statistically significant (95% CI, 0.05-1.74; P = .18) ( Figure 4 )." 
